Lp(a) Screening: Higher CVD Risk in First-Degree Relatives 08/31/25
Welcome to Cardiology Today – Episode recorded on August 31, 2025. Your source for the latest cardiology research findings from top medical journals.
đ§ Listen to This Episode
đ Episode Summary
This episode covers 8 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
đ Featured Research Articles
Article 1: Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884768
Summary: This study found no significant differences in all-cause mortality, stroke, or rehospitalization between TAVR and SAVR at three years in low-risk patients aged 60-75 with severe aortic stenosis, supporting TAVR as a reasonable option in this population. However, there was a higher incidence of bioprosthetic valve failure after TAVR, warranting longer-term follow-up.
Article 2: Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884047
Summary: The PRADA II trial demonstrated that sacubitril-valsartan did not significantly reduce the incidence of cancer therapy-related cardiac dysfunction in patients undergoing adjuvant breast cancer treatment with anthracyclines and/or trastuzumab. These findings do not support the routine use of sacubitril-valsartan for primary prevention of cardiotoxicity in this setting.
Article 3: Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879562
Summary: This study highlights the importance of intermediate-effect genetic variants (IEVs) in modulating the expression of hypertrophic cardiomyopathy (HCM). Understanding the clinical impact of these IEVs is crucial for unraveling the complex genetic architecture of HCM and improving risk stratification.
Article 4: Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40878766
Summary: The DOUBLE-CHOICE trial showed that a minimalist anesthesia approach for transfemoral TAVI is non-inferior to standard of care regarding safety and efficacy. These results support the broader adoption of minimalist TAVI strategies to optimize resource utilization and patient outcomes.
Article 5: Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40878676
Summary: This research identifies that in antiphospholipid syndrome (APS), the abnormal proliferation of microvascular endothelial cells leading to vasculopathy is driven by YAP1 and CCN2 signaling pathways. This discovery provides potential therapeutic targets for treating APS vasculopathy, where targeted treatment options are currently lacking.
Article 6: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886179
Summary: The TAILORED-CHIP trial found that a tailored antiplatelet strategy involving early escalation and subsequent de-escalation based on platelet function testing did not significantly reduce major adverse cardiovascular events compared to a standard antiplatelet strategy in high-risk patients undergoing complex PCI. This suggests that routine tailoring of antiplatelet therapy based on platelet function in this setting may not provide additional benefit.
Article 7: Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886161
Summary: This analysis of the GALACTIC-HF trial demonstrates that low serum magnesium concentrations are associated with increased risk of adverse cardiovascular outcomes in patients with heart failure with reduced ejection fraction (HFrEF). The findings suggest that magnesium status may be an important prognostic marker in HFrEF.
Article 8: Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886132
Summary: This study indicates that first-degree relatives of individuals with elevated lipoprotein(a) levels have an increased risk of cardiovascular events. Screening first-degree relatives for elevated Lp(a) may identify individuals at risk who could benefit from early intervention.
đ Full Episode Transcript
Today’s date is August 31, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis. This study found no significant differences in all-cause mortality, stroke, or rehospitalization between TAVR and SAVR at three years in low-risk patients aged 60-75 with severe aortic stenosis, supporting TAVR as a reasonable option in this population. However, there was a higher incidence of bioprosthetic valve failure after TAVR, warranting longer-term follow-up.
Article number two. Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. The PRADA II trial demonstrated that sacubitril-valsartan did not significantly reduce the incidence of cancer therapy-related cardiac dysfunction in patients undergoing adjuvant breast cancer treatment with anthracyclines and/or trastuzumab. These findings do not support the routine use of sacubitril-valsartan for primary prevention of cardiotoxicity in this setting.
Article number three. Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants. This study highlights the importance of intermediate-effect genetic variants (IEVs) in modulating the expression of hypertrophic cardiomyopathy (HCM). Understanding the clinical impact of these IEVs is crucial for unraveling the complex genetic architecture of HCM and improving risk stratification.
Article number four. Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial. The DOUBLE-CHOICE trial showed that a minimalist anesthesia approach for transfemoral TAVI is non-inferior to standard of care regarding safety and efficacy. These results support the broader adoption of minimalist TAVI strategies to optimize resource utilization and patient outcomes.
Article number five. Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling. This research identifies that in antiphospholipid syndrome (APS), the abnormal proliferation of microvascular endothelial cells leading to vasculopathy is driven by YAP1 and CCN2 signaling pathways. This discovery provides potential therapeutic targets for treating APS vasculopathy, where targeted treatment options are currently lacking.
Article number six. Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. The TAILORED-CHIP trial found that a tailored antiplatelet strategy involving early escalation and subsequent de-escalation based on platelet function testing did not significantly reduce major adverse cardiovascular events compared to a standard antiplatelet strategy in high-risk patients undergoing complex PCI. This suggests that routine tailoring of antiplatelet therapy based on platelet function in this setting may not provide additional benefit.
Article number seven. Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. This analysis of the GALACTIC-HF trial demonstrates that low serum magnesium concentrations are associated with increased risk of adverse cardiovascular outcomes in patients with heart failure with reduced ejection fraction (HFrEF). The findings suggest that magnesium status may be an important prognostic marker in HFrEF.
Article number eight. Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study. This study indicates that first-degree relatives of individuals with elevated lipoprotein(a) levels have an increased risk of cardiovascular events. Screening first-degree relatives for elevated Lp(a) may identify individuals at risk who could benefit from early intervention.
Thank you for listening to Cardiology Today.
đ Keywords
Medical Topics: Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine
Journals: New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology
âšī¸ About Cardiology Today
Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.
Subscribe to stay updated with the latest cardiology research âĸ Share with colleagues âĸ Follow for more medical content